The Global Asthma Report 2022.
10.5588/ijtld.22.1010 · 2022
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
10.1016/j.rmed.2006.03.031 · 2006
New Targeted Therapies for Uncontrolled Asthma
10.1016/j.jaip.2019.03.022 · 2019
Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia
10.1016/j.jaci.2015.05.037 · 2016
Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients
10.1016/j.jaci.2019.01.027 · 2019
Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives.
10.1007/s40265-017-0777-2 · 2017
The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation.
10.1186/s12931-018-0893-x · 2018
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes
10.1164/ajrccm/144.1.51 · 1991
Elevated Prostaglandin D2 (PGD2) Levels in Bronchoalveolar Lavage Fluid (BALF) in Severe Asthma.
2010
Targeting cell signaling in allergic asthma
10.1038/s41392-019-0079-0 · 2019
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161
10.1038/ni.2104 · 2011
Cytokine-induced endogenous production of prostaglandin D2 is essential for human group 2 innate lymphoid cell activation
10.1016/j.jaci.2018.10.069 · 2019
Emerging roles of DP and CRTH2 in allergic inflammation
10.1016/j.molmed.2006.02.005 · 2006
Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2
10.1084/jem.193.2.255 · 2001
Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor
10.1186/s12931-021-01852-3 · 2021
Co-operative signalling through DP(1) and DP(2) prostanoid receptors is required to enhance leukotriene C(4) synthesis induced by prostaglandin D(2) in eosinophils.
10.1111/j.1476-5381.2010.01086.x · 2011
Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events
10.1183/09031936.00061614 · 2015
Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction
10.1152/jappl.1989.66.4.1685 · 1989
Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells.
10.1046/j.0019-2805.2001.01340.x · 2002
Effects of a thromboxane receptor antagonist on prostaglandin D2 and histamine induced bronchoconstriction in man
10.1111/j.1365-2125.1994.tb04249.x · 1994
PPAR-γ promotes type 2 immune responses in allergy and nematode infection
10.1126/sciimmunol.aal5196 · 2017
PPARγ enhances ILC2 function during allergic airway inflammation via transcription regulation of ST2.
10.1038/s41385-020-00339-6 · 2021
PPAR and immune system—what do we know?
10.1016/s1567-5769(02)00057-7 · 2002
Physiological levels of 15-deoxy-Delta12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-gamma ligation
10.4049/jimmunol.175.9.5744 · 2005
PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.
10.1038/s41467-021-22764-2 · 2021
The devil’s in the detail: cell-specific role of PPARγ in ILC2 activation by IL-33.
10.1038/s41385-020-00363-6 · 2021
PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors
10.1016/j.bcp.2007.03.023 · 2007
Antagonists of the prostaglandin D2 receptor CRTH2
10.1358/dnp.2008.21.6.1246831 · 2008
9alpha,11beta-PGF2 and its stereoisomer PGF2alpha are novel agonists of the chemoattractant receptor, CRTH2
10.1016/j.febslet.2005.11.052 · 2006
15-Deoxy-Delta-12,14-Prostaglandin J2 Inhibits Lung Inflammation and Remodeling in Distinct Murine Models of Asthma.
10.3389/fimmu.2017.00740 · 2017
15d-PGJ2: the anti-inflammatory prostaglandin?
10.1016/j.clim.2004.09.008 · 2005
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2
10.1038/sj.bjp.0704973 · 2002
CRTH2 antagonists in asthma: current perspectives
2017
New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant
10.1016/j.phrs.2019.104490 · 2020
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
10.1016/s2213-2600(16)30179-5 · 2016
DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.
2019
Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).
10.1016/j.jaci.2021.12.759 · 2022
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.
10.1016/s2213-2600(20)30412-4 · 2021
Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).
10.1016/j.eclinm.2021.100847 · 2021
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
10.1016/j.jaci.2019.02.015 · 2019
